HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Eosinophilic granulomatosis with polyangiitis — Clinical Guidelines

Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare ANCA-associated systemic vasculitis characterized by asthma, eosinophilia, and granulomatous or vasculitic involvement of multiple organs 7.

Diagnosis

Key Criteria: Asthma, peripheral blood eosinophilia, and major organ involvement (e.g., lung, kidney, peripheral nerves) 1 9 10.

Recommended Tests: ANCA testing, comprehensive blood count, imaging studies (e.g., chest CT, MRI of affected areas), and nerve conduction studies 1 5.

Classification Criteria: 2022 ACR/EULAR criteria show improved validation over older criteria, particularly in diverse populations 1 6 8.

Red Flags: Persistent asthma, unexplained peripheral neuropathy, and multi-organ involvement raise suspicion for EGPA 5.

Management

First-Line Treatments: High-dose corticosteroids, often with cyclophosphamide for severe disease 7.

Adjunctive Therapies:

- Mepolizumab: Reduces eosinophil counts and has shown efficacy in maintenance therapy 3. - Benralizumab: Anti-IL-5 receptor monoclonal antibody effective in refractory cases 2 4.

Glucocorticoid Sparing: Use of biologic agents like mepolizumab to reduce reliance on corticosteroids 3 4.

Special Populations

Pregnancy: Limited data; management typically involves close monitoring and individualized treatment plans balancing maternal and fetal safety 7.

Elderly: Tailored approach considering comorbidities and potential drug interactions; close monitoring essential 7.

Key Recommendations

Utilize the 2022 ACR/EULAR classification criteria for accurate diagnosis of EGPA (Evidence: Strong 1 9 10).

Incorporate biologic agents such as mepolizumab or benralizumab for patients with refractory or severe EGPA to reduce corticosteroid dependency (Evidence: Moderate 2 3 4).

Employ comprehensive diagnostic testing including ANCA, blood counts, and imaging to confirm multi-organ involvement (Evidence: Moderate 1 5).

Individualize treatment plans for special populations like pregnant women and the elderly, considering potential risks and benefits (Evidence: Expert opinion 7).

References

1 Liu Y, Zhan M, Chen SA, Jin X, Luo X, Jiang L. Validation of the 2022 ACR/EULAR classification criteria for eosinophilic granulomatosis with polyangiitis in a Chinese cohort. Clinical rheumatology 2026. link 2 Spataro F, Solimando AG, Di Girolamo A, Vacca A, Ria R. Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies. European journal of clinical investigation 2025. link 3 Rubiño Juárez F, García de Vicuña R, Vicente E, Rodríguez Almaraz E, Lozano Rivas N, Freire González M et al.. Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: Data from a Spanish retrospective multicentric register from Rheumatology departments. Reumatologia clinica 2025. link 4 Yukishima T, Yonezawa H, Aono Y, Yamaguchi K, Otsuki Y, Ohmura SI. Successful switching treatment of mepolizumab for refractory eosinophilic granulomatosis with polyangiitis and multiple organ dysfunction under benralizumab treatment: A case report. Modern rheumatology case reports 2025. link 5 Solans-Laqué R, Rúa-Figueroa I, Blanco Aparicio M, García Moguel I, Blanco R, Pérez Grimaldi F et al.. Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA). European journal of internal medicine 2024. link 6 Han Q, Li J, Wang J, Zhang L, Zhang J. Application of the 2022 ACR/EULAR criteria to Chinese patients with previously diagnosed eosinophilic granulomatosis with polyangiitis: The concordance rate between the 2022 ACR/EULAR criteria and the 1990 criteria for EGPA in China. Medicine 2024. link 7 Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S et al.. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nature reviews. Rheumatology 2023. link 8 Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 ACR/EULAR Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. The Journal of rheumatology 2023. link 9 Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A et al.. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis & rheumatology (Hoboken, N.J.) 2022. link 10 Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A et al.. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Annals of the rheumatic diseases 2022. link 11 Nagata K, Yamamoto S, Miyoshi K, Sato M, Arino Y, Mikami Y. A Diagnostic Algorithm for Eosinophilic Granulomatosis with Polyangiitis Initially Diagnosed as Lumbar Disc Hernia or Lumbar Spinal Stenosis: Personal Experience and Review of the Literature. Acta medica Okayama 2016. link

Eosinophilic granulomatosis with polyangiitis